ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates September 05, 2017
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates August 29, 2017
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates Juli 05, 2017
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Press release Key program features and updates: Juni 15, 2017
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference Press release LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Juni 13, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release Key Updates Juni 08, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Press release Key Updates Mai 31, 2017